Cerebral Venous Sinus Thrombosis in Women: Subgroup Analysis of the VENOST Study.
Journal
Stroke research and treatment
ISSN: 2090-8105
Titre abrégé: Stroke Res Treat
Pays: United States
ID NLM: 101529024
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
11
2019
accepted:
15
05
2020
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
22
9
2020
Statut:
epublish
Résumé
Early diagnosis of cerebral venous sinus thrombosis (CVST) associated with reproductive health-related risk factors (RHRF) including pregnancy, puerperium, and oral contraceptive (OC) use can prevent severe neurological sequelae; thus, the symptoms must be documented in detail for each group. Out of 1144 patients with CVST, a total of 777 women were enrolled from a multicenter for the study of cerebral venous sinus thrombosis (VENOST). Demographic, biochemical, clinical, and radiological aspects were compared for 324 cases with RHRF and 453 cases without RHRF. The mean age of the RHRF (-) group (43.2 ± 13 years) was significantly higher than of the RHRF (+) group (34 ± 9 years). A previous history of deep venous thrombosis (3%), isolated cavernous sinus involvement (1%), cranial neuropathy (13%), comorbid malignancy (7%), and its disability scores after 12 months (9%) were significantly higher in the RHRF (-) group. The RHRF (+) group consisted of 44% cases of puerperium, 33% cases of OC users and 23% of pregnant women. The mean age was found to be higher in OC users (38 ± 9 years). A previous history of deep venous thrombosis was slightly higher in the pregnancy subgroup (4%). Epileptic seizures were more common in the puerperium group (44%). The results of our study indicate that the risk of CSVT increases parallel to age, OC use, and puerperium period. In addition, when considering the frequency of findings and symptoms, epileptic seizures in the puerperium subgroup of the RHRF (+) group and malignancies in the RHRF (-) group may accompany the CSVT. In daily practice, predicting these risks for the CSVT and early recognition of the symptoms will provide significant benefits to patients.
Sections du résumé
BACKGROUND
BACKGROUND
Early diagnosis of cerebral venous sinus thrombosis (CVST) associated with reproductive health-related risk factors (RHRF) including pregnancy, puerperium, and oral contraceptive (OC) use can prevent severe neurological sequelae; thus, the symptoms must be documented in detail for each group.
METHODS
METHODS
Out of 1144 patients with CVST, a total of 777 women were enrolled from a multicenter for the study of cerebral venous sinus thrombosis (VENOST). Demographic, biochemical, clinical, and radiological aspects were compared for 324 cases with RHRF and 453 cases without RHRF.
RESULTS
RESULTS
The mean age of the RHRF (-) group (43.2 ± 13 years) was significantly higher than of the RHRF (+) group (34 ± 9 years). A previous history of deep venous thrombosis (3%), isolated cavernous sinus involvement (1%), cranial neuropathy (13%), comorbid malignancy (7%), and its disability scores after 12 months (9%) were significantly higher in the RHRF (-) group. The RHRF (+) group consisted of 44% cases of puerperium, 33% cases of OC users and 23% of pregnant women. The mean age was found to be higher in OC users (38 ± 9 years). A previous history of deep venous thrombosis was slightly higher in the pregnancy subgroup (4%). Epileptic seizures were more common in the puerperium group (44%).
CONCLUSION
CONCLUSIONS
The results of our study indicate that the risk of CSVT increases parallel to age, OC use, and puerperium period. In addition, when considering the frequency of findings and symptoms, epileptic seizures in the puerperium subgroup of the RHRF (+) group and malignancies in the RHRF (-) group may accompany the CSVT. In daily practice, predicting these risks for the CSVT and early recognition of the symptoms will provide significant benefits to patients.
Identifiants
pubmed: 32953038
doi: 10.1155/2020/8610903
pmc: PMC7481993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8610903Informations de copyright
Copyright © 2020 Derya Uluduz et al.
Déclaration de conflit d'intérêts
The authors declared that they have no conflicts of interest for this article.
Références
J Emerg Med. 2012 Apr;42(4):413-6
pubmed: 21945504
Stroke. 2005 Sep;36(9):1927-32
pubmed: 16100024
Curr Cardiol Rep. 2014;16(10):532
pubmed: 25239155
Neurosurg Focus. 2009 Nov;27(5):E5
pubmed: 19877796
Stroke. 2000 Dec;31(12):2948-51
pubmed: 11108754
Womens Health (Lond). 2007 Jul;3(4):487-502
pubmed: 19804024
Stroke. 2001 Aug;32(8):1793-9
pubmed: 11486107
J Thromb Haemost. 2006 Mar;4(3):529-35
pubmed: 16460435
J Neurointerv Surg. 2017 Jan;9(1):34-38
pubmed: 27095355
J Thromb Haemost. 2008 Apr;6(4):632-7
pubmed: 18248600
J Clin Neurosci. 2017 May;39:9-15
pubmed: 28274514
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):814-6
pubmed: 12754362
Medicine (Baltimore). 1986 Mar;65(2):82-106
pubmed: 3512953
Neurol Clin. 1992 Feb;10(1):87-111
pubmed: 1557011
Obstet Gynecol. 2011 Mar;117(3):691-703
pubmed: 21343773
Nat Rev Cardiol. 2015 Aug;12(8):464-74
pubmed: 26076949
Stroke. 2000 Jun;31(6):1274-82
pubmed: 10835444
Obstet Gynecol. 2014 May;123(5):987-96
pubmed: 24785851
Stroke. 2004 Mar;35(3):664-70
pubmed: 14976332
Stroke. 2009 Jul;40(7):2356-61
pubmed: 19478226
Br Med J. 1970 Apr 25;2(5703):203-9
pubmed: 5443406
PLoS One. 2017 Jul 27;12(7):e0182041
pubmed: 28750087
N Engl J Med. 2005 Apr 28;352(17):1791-8
pubmed: 15858188
Stroke. 1993 Dec;24(12):1880-4
pubmed: 8248971
J Stroke Cerebrovasc Dis. 2017 Aug;26(8):1848-1857
pubmed: 28583818
Ann Intern Med. 2005 Nov 15;143(10):697-706
pubmed: 16287790